Cancer biologics Market Size and Demand Forecast 2026–2030

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer biologics market from 2026–2035 with trusted insights from The Business Research Company

How much is the Cancer biologics Market valued at in 2026, and what valuation is forecast for 2030?

The cancer biologics market has experienced strong growth in recent years. It is projected to expand from $129.05 billion in 2025 to $140.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. The historical growth of this market can be attributed to an increasing global incidence of cancer, a rising need for advanced cancer therapies, intensified oncology research endeavors, the recognized limitations of conventional chemotherapy, and the proliferation of hospital-based cancer treatment centers.

The cancer biologics market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $203.29 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Key factors driving this growth during the forecast timeframe include progress in cell and gene therapy platforms, a rise in approvals for new biologics, the expansion of personalized oncology therapies, increased investment in cancer biologics research and development (R&D), and an increase in biologics manufacturing capabilities. Prominent trends expected during this period involve a growing embrace of immunotherapy and targeted biologic interventions, the expanded application of monoclonal antibodies within oncology, the development of cell and gene therapy solutions for cancer, an increase in cancer vaccine development initiatives, and an enhanced emphasis on combination biologic treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What Drivers Are Influencing The Growth Of The Cancer biologics Market?

The increasing incidence of chronic diseases is a primary driver behind the expansion of the cancer biologics market. These long-term conditions impair the health of individuals, including those with disabilities, with cancer being one of the most prevalent chronic illnesses. The most frequently encountered cancers include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For instance, in February 2024, reports from the Centers for Disease Control and Prevention (CDC), a US-based public health agency, revealed that a growing number of people in America are dealing with multiple chronic conditions, with 42% experiencing two or more, and 12% having five or more. Thus, the rising prevalence of chronic diseases is projected to propel the growth of the cancer biologics market in the coming years.

What Segments Are Included Within The Cancer biologics Market?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

Which Market Trends Are Opening Growth Opportunities In The Cancer biologics Market?

Major companies active within the cancer biologics market are primarily focusing on the development of innovative therapies, such as bispecific antibodies and biomarker guided biologics. This strategic emphasis aims to enhance treatment efficacy and target particular cancer cells more effectively. Bispecific antibodies are considered a next-generation biologic therapy, capable of binding concurrently to two distinct epitopes or targets, while biomarker guided biologics are specifically designed to target tumor cells identified through certain molecular markers. For example, in November 2024, the Dublin-based global biopharmaceutical company, Jazz Pharmaceuticals Public Limited Company, received approval from the U.S. Food & Drug Administration (FDA) for the accelerated pathway of Ziihera (zanidatamab hrii). This was granted for adults with previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This approval signifies the first and only dual HER2 targeted bispecific antibody for this specific indication, thereby extending the application of HER2 targeted biologic therapy into a new tumor type, moving beyond established indications.

Who Are The Core Companies Influencing Trends In The Cancer biologics Market?

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Which Regions Are Projected To Dominate The Cancer biologics Market In The Coming Years?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer biologics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp

Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company

Point Of Care Diagnostics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Cell Culture Consumables And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Metabolomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795